Features of acute coronary syndrome after a COVID-19 in the aspect of pulmonary hypertension

Abstract

BACKGROUND: After recovery from COVID-19 patients may develop new risk factors that lead to changes in cardiopulmonary interactions, i.e. an increase in the afterload on the right ventricle due to increased pressure in the pulmonary artery and change in pulmonary vascular resistance. It can be assumed that the presence of such a spectrum of problems can influence the severity of dyspnea and the development of pathogenetic events (pulmonary hypertension, right ventricular failure, subendocardial ischemia), which in turn can determine the outcome.

AIM: To identify the characteristics of acute coronary syndrome after a COVID-19, taking into account angiographic data on coronary artery lesions and hemodynamic manifestations.

MATERIALS AND METHODS: A comparative analysis of the clinical and hemodynamic consequences of the COVID-19 and the development of acute coronary syndrome in 157 patients was carried out. The group 1 included 69 patients who had had COVID-19 (vaccinated — 24.6%) during the 6 months preceding acute coronary syndrome; group 2 — 88 patients without a history of COVID-19 (vaccinated — 42%). The 12-lead electrocardiogram has been used in the diagnosis of subendocardial ischemia in acute coronary syndrome. The ST segment displacement in lead aVR was analyzed.

RESULTS: After COVID-19, dispnoe occurred in 52% of the patients and in 14.8% without previous infection. Echocardiographic signs of right ventricular overload were present in 42% of the patients in group 1 and 10.2% in group 2. The mean pressure in the pulmonary artery was increased after COVID-19 in 58% of the patients in group 1 and in 10.2% of group 2 in the range from 20 to 24 mm Hg and in the range from 25 to 36 mm Hg in 29% of the patients in group 1 and 2.3% of the patients in group 2. The average value of left ventricular ejection fraction in the patients who had had COVID-19 was 55.9 ± 14%, which was less than in the patients in the control group (63.2 ± 5.5%; p < 0.001). ST segment elevation in lead aVr indicated high incidence of subendocardial ischemia. 40.6% in group 1, and 11.4% in group 2 (χ² = 17.9; p < 0.001); in group 1 vaccinated — 17.6%, and not vaccinated — 48.1% (χ² = 4.9; p = 0.027), in group 2 vaccinated — 8.1%, and not vaccinated — 13.7% (χ² = 0.7; p = 0.41). All the patients had drug-eluting stents implanted in the infarct-related artery. After stenting, no recurrence of pain or further increase in chest pain was observed.

CONCLUSIONS: After coronavirus infection COVID-19, 58% of patients have increased mean pressure in the pulmonary artery in the range from 20 to 24 mm Hg and in the range from 25 to 36 mm Hg in 29%. Atherothrombosis is the main mechanism of acute coronary syndrome after COVID-19 coronavirus infection. The main feature of acute coronary syndrome after a coronavirus infection COVID-19 is increased pressure in the pulmonary artery after a lung injury, which must be taken into account when planning surgical treatment tactics and management tactics in the postoperative period.

Keywords

postсovid syndrome / acute coronary syndrome / pulmonary hypertension / lung damage / coronary artery stenting

References

[1] Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC / AHA / ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of cardiology / American Heart Association Task Force on Practice Guidelines (ACC / AHA / ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation. 2003;108(9):1146–1162. doi: 10.1161/01.CIR.0000073597.57414.A9

[2] Cheitlin M.D., Armstrong W.F., Aurigemma G.P., et al. ACC / AHA / ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of cardiology / American Heart Association Task Force on Practice Guidelines (ACC / AHA / ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography) // Circulation. 2003. Vol. 108, N. 9. P. 1146–1162. doi: 10.1161/01.CIR.0000073597.57414.A9

[3] Golukhova EZ, Sokolova NYu, Bulaeva NI. New coronavirus infection COVID-19: the view of сardiologists (review). Creative Cardiology. 2020;14(1):5–15. EDN: UKZNDB doi: 10.24022/1997-31872020-14-1-5-15

[4] Голухова Е.З., Соколова Н.Ю., Булаева Н.И. Взгляд кардиолога на проблему пандемии новой коронавирусной инфекции COVID-19 (обзор литературы) // Креативная кардиология. 2020. Т. 14, № 1. C. 5–15. EDN: UKZNDB doi: 10.24022/1997-31872020-14-1-5-15

[5] Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. Clinical features of post-COVID period. Results of an International Register “Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)” (12-month follow-up). Russian Journal of Cardiology. 2023;28(1):9–27. EDN: VHEPAD doi: 10.15829/1560-4071-2023-5270

[6] Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г., и др. Клинические особенности постковидного периода. Результаты международного регистра “Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 (АКТИВ SARS-CoV-2)” (12 месяцев наблюдения) // Российский кардиологический журнал. 2023. Т. 28, № 1. С. 9–27. EDN: VHEPAD doi: 10.15829/1560-4071-2023-5270

[7] Ageev FT, Ovchinnikov AG, Mareev VYu, Belenkov YuN. How to treat diastolic heart dysfunction? Consilium medicum. 2002;4(3):114–117. (In Russ.) EDN: WYKOHH

[8] Агеев Ф.Т., Овчинников А.Г., Мареев В.Ю., Беленков Ю.Н. Как лечить диастолическую дисфункцию сердца? // Consilium medicum. 2002. Т. 4, № 3. С. 114–117. EDN: WYKOHH

[9] Naumov AB, Marchenko SP, Khubulava GG, et al. Assessing hemodynamics: a scientific and practical approach: textbook. Saint Petersburg: Russian Book Chamber; 2022. 44 p. (In Russ.) EDN: YAHFDI doi: 10.13140/RG.2.2.36443.85283

[10] Наумов А.Б., Марченко С.П., Хубулава Г.Г., и др. Оценка гемодинамики: научно-практический подход: учебное пособие. Санкт-Петербург: Российская книжная палата, 2022. 44 с. EDN: YAHFDI doi: 10.13140/RG.2.2.36443.85283

[11] Parasuraman S, Walker S, Loudon BL, et al. Assessment of pulmonary artery pressure by echocardiography — a comprehensive review. Int J Cardiol Heart Vasc. 2016;12(3):45–51. doi: 10.1016/j.ijcha.2016.05.011

[12] Parasuraman S., Walker S., Loudon B.L., et al. Assessment of pulmonary artery pressure by echocardiography — a comprehensive review // Int J Cardiol Heart Vasc. 2016. Vol. 12, N. 3. P. 45–51. doi: 10.1016/j.ijcha.2016.05.011

[13] Chashchin MG, Gorshkov AYu, Drapkina OM. Acute coronary syndrome in COVID-19 patients. Cardiovascular Therapy and Prevention. 2021;20(5):107–114. EDN: KQOWON doi: 10.15829/1728-8800-2021-2806

[14] Чащин М.Г., Горшков А.Ю., Драпкина О.М. Острый коронарный синдром у пациентов с COVID-19 // Кардиоваскулярная терапия и профилактика. 2021. Т. 20, № 5. С. 107–114. EDN: KQOWON doi: 10.15829/1728-8800-2021-2806

[15] Kokov LS, Petrikov SS, Pisankina MM, et al. Course and outcomes of acute coronary syndrome in the presence of new coronavirus infection COVID-19. Russian Sklifosovsky Journal Emergency Medical Care. 2022;11(2):238–248. EDN: EKZLWK doi: 10.23934/2223-9022-2022-11-2-238-248

[16] Коков Л.С., Петриков С.С., Писанкина М.М., и др. Течение и исходы острого коронарного синдрома в условиях новой коронавирусной инфекции COVID-19 // Журнал им. Н.В. Склифосовского Неотложная медицинская помощь. 2022. Т. 11, № 2. С. 238–248. EDN: EKZLWK doi: 10.23934/2223-9022-2022-11-2-238-248

[17] Drapkina OM, Kravchenko AYa, Budnevskiy AV, et al. Acute coronary syndrome during the pandemic new coronavirus infection. Rational Pharmacotherapy in Cardiology. 2023;19(1):65–70. EDN: SYEUIN doi: 10.20996/1819-6446-2023-01-04

[18] Драпкина О.М., Кравченко А.Я., Будневский А.В., и др. Острый коронарный синдром в период пандемии новой коронавирусной инфекции // Рациональная фармакотерапия в кардиологии. 2023. Т. 19, № 1. С. 65–70. EDN: SYEUIN doi: 10.20996/1819-6446-2023-01-04

[19] Alekyan BG, Boytsov SA, Ganyukov VI, Manoshkina EM. Impact of the COVID-19 Pandemic on myocardial revascularization in patients with acute coronary syndrome in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2022;18(4):411–419. EDN: BYSCRX doi: 10.20996/1819-6446-2022-08-03

[20] Алекян Б.Г., Бойцов С.А., Ганюков В.И., Маношкина Е.М. Влияние пандемии COVID-19 на реваскуляризацию миокарда у пациентов с острым коронарным синдромом в Российской Федерации // Рациональная фармакотерапия в кардиологии. 2022. Т. 18, № 4. С. 411–419. EDN: BYSCRX doi: 10.20996/1819-6446-2022-08-03

[21] Marchenko SP, Shikhverdiev NN, Khubulava GG. Ischemic heart disease and its surgical treatment of patients with cardiology profile 3. Section 3. Saint Petersburg; 2011. 112 p. (In Russ.)

[22] Марченко С.П., Шихвердиев Н.Н., Хубулава Г.Г. Ишемическая болезнь сердца и ее хирургическое лечение пациентов кардиологического профиля 3. Раздел 3. Санкт-Петербург, 2011. 112 с.

[23] Sokolov AA, Martsinkevich GI. Heart failure in patients with preserved ejection fraction-pumping heart failure? Kardiologiia. 2018;58(6):79–84. EDN: XPUSLJ doi: 10.18087/cardio.2018.6.10125

[24] Соколов А.А., Марцинкевич Г.И. Сердечная недостаточность у пациентов с сохраненной фракцией выброса левого желудочка — насосная несостоятельность сердца? // Кардиология. 2018. Т. 58, № 6. C. 79–84. EDN: XPUSLJ doi: 10.18087/cardio.2018.6.10125

[25] Khubulava GG, Shikhverdiev NN, Paivin AA, et al. Protection of the myocardium during heart surgery. Saint Petersburg: Diton; 2013. 143 p. (In Russ.) EDN: VSPSBL

[26] Хубулава Г.Г., Шихвердиев Н.Н., Пайвин А.А., и др. Защита миокарда при операциях на сердце. Санкт-Петербург: Дитон, 2013. 143 c. EDN: VSPSBL

RIGHTS & PERMISSIONS

Eco-Vector